Kingsman Wealth Management Inc. Has $3.59 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• Kingsman Wealth Management Inc. increased its stake in Boston Scientific Corporation by 24.7%, now holding $3.59 million worth of shares, making it the 12th largest holding in their portfolio.
• Boston Scientific reported better-than-expected earnings, with $0.75 EPS for the last quarter, surpassing the consensus estimate of $0.72, and a revenue increase of 22.8% year-over-year.
• Analysts maintain a strong outlook on Boston Scientific, with three strong buy ratings and an average target price of $118.17 for the stock.

Kingsman Wealth Management Inc. raised its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 24.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,433 shares of the medical equipment provider's stock after acquiring an additional 6,622 shares during the period. Boston Scientific makes up about 2.2% of Kingsman Wealth Management Inc.'s portfolio, making the stock its 12th biggest holding. Kingsman Wealth Management Inc.'s holdings in Boston Scientific were worth $3,591,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. 1248 Management LLC bought a new position in Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $27,000. Ameriflex Group Inc. acquired a new position in Boston Scientific during the 4th quarter worth approximately $31,000. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management boosted its position in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after buying an additional 373 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on BSX. BTIG Research reiterated a "buy" rating and issued a $127.00 price target on shares of Boston Scientific in a research note on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, September 19th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Truist Financial raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Finally, Raymond James Financial boosted their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $118.17.

Boston Scientific Stock Performance

BSX stock opened at $98.03 on Friday. The firm has a market cap of $145.26 billion, a PE ratio of 58.35, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $103.90 and a 200-day moving average price of $102.06. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last quarter. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.